SOCRA Protocol Deviations and Violations 3

Question 1

ICH E6(R2) Section 5.20.1 states that a sponsor's Quality Management System should include risk-based approaches. How does this apply to protocol deviation management?

Accepted Answer

Sponsors should focus oversight resources on deviations that pose the greatest risk to subject safety and data reliability

Answer

All deviations must be treated equally regardless of their impact on subject safety

Answer

Risk-based monitoring eliminates the need to report deviations to the IRB

Answer

Only deviations identified by the FDA need to be included in quality management

Question 2

A subject withdraws consent during a study visit but the CRC continues collecting scheduled data before the withdrawal is formally processed. This situation BEST represents:

Accepted Answer

A serious protocol violation that also constitutes a breach of ethical principles

Answer

A minor administrative deviation with no ethical implications

Answer

Standard practice when data collection is nearly complete

Answer

A sponsor-authorized deviation under the protocol's withdrawal procedures

Question 3

Which of the following is a key indicator that a site has a systemic protocol compliance problem rather than isolated deviations?

Accepted Answer

Recurring deviations of the same type across multiple subjects and multiple monitoring visits

Answer

One deviation occurring in a single subject over a 3-year study

Answer

A deviation involving a laboratory timing window noted once

Answer

A single consent timing deviation that was immediately corrected

Question 4

A subject was randomized into a study but was later found to have been ineligible due to a prohibited concomitant medication. The data monitor committee (DMC) is evaluating the study. This deviation should PRIMARILY be reported to:

Accepted Answer

The IRB, the sponsor, and documented in the regulatory binder

Answer

Only the sponsor's data management team

Answer

The FDA directly by the site, bypassing the sponsor

Answer

No reporting is needed if the subject completed the study safely

Question 5

Under 21 CFR 312.66, an investigator must promptly report to the IRB any protocol deviations made to:

Accepted Answer

Eliminate apparent immediate hazards to human subjects

Answer

Reduce administrative burden on the site staff

Answer

Accommodate sponsor requests for accelerated enrollment

Answer

Simplify the subject visit schedule for convenience

Question 6

At a clinical site, all protocol deviations are being captured in a deviation log. According to GCP, which of the following is MOST important about this log?

Accepted Answer

It should be complete, contemporaneous, and accessible for review by monitors, auditors, and inspectors

Answer

It should only include deviations identified by the sponsor's CRA during monitoring visits

Answer

It should be maintained by the sponsor rather than the site

Answer

It only needs to include deviations that were reported to the FDA

Question 7

A site receives a sponsor letter stating that a protocol deviation involving incorrect IP storage temperatures was identified. The sponsor concludes the IP is still acceptable for use. What should the site do NEXT?

Accepted Answer

Document the deviation and the sponsor's assessment in the site's deviation log and regulatory binder

Answer

Dispose of all affected IP immediately without further documentation

Answer

Continue using the IP without any additional action since the sponsor approved it

Answer

Notify the FDA independently of the sponsor's conclusion